Floatz logo

FLUTICASONE

Acute Lymphocytic Leukemia

Virginia Commonwealth UniversitySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Acute Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
SPANLECORTEMLOCEL
Novartis Pharmaceuticals
Phase 2BB
Lipitor
Loyola University
Phase 3BB
Basiliximab
City of Hope Medical Center
Phase 2BB
18f-flt
University of Oklahoma
Phase 2B
Allopurinol
Masonic Cancer Center, University of Minnesota
Phase 2B

View all 42 →

Same molecule, other indications

FLUTICASONE is also rated in:

Unspecified Adult Solid Tumor, Protocol SpecificDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
Chronic Phase Chronic Myelogenous LeukemiaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →